Friday, December 30, 2016 4:33:02 AM
HTTP://immunosym.org/program/poster-sessions
Poster Session A: Humoral Immunity for Diagnosis and Therapy, Immune Checkpoints and Stimulatory Receptors, and Therapies Targeting T cells
Thursday, February 23 2017: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM
BOARD H3
MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial. (Abstract 154)
First Author: Martin Scurr
HTTP://medicine.caerdydd.ac.uk/media/filer_public/85/a0/85a0407a-e02a-4086-bfb3-6fc902eb7ecc/science_in_practice_infection__immunity_2014.pdf
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM